Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257619 · ClinicalTrials.gov registry record · Phase 2
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02257619 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 9 participants.
The verdict
NCT02257619, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objectives of this study were to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion), and to evaluate and compare the overall survival of subjects with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) when treated with itacitinib in combination with docetaxel versus docetaxel alone (Part 2, randomized portion).
Interventions
- DRUG Itacitinib
- DRUG docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-09-24 |
| Est. Completion | 2016-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257619
The ClinicalTrials.gov registry entry for NCT02257619 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itacitinib is the first listed.
NCT02257619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02257619 about?
NCT02257619 is a clinical study titled "Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer". The primary objectives of this study were to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion), and to evaluate and compare the overall survival of subjects with previously treated advanced or m...
What is the current status of trial NCT02257619?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-09-24. Estimated completion is 2016-04-05.
What interventions are being tested in trial NCT02257619?
The interventions under investigation include: Itacitinib (DRUG), docetaxel (DRUG).
Who is sponsoring clinical trial NCT02257619?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.